NIH Ebola vaccines trial meets 1,500 enrollment goal
This article was originally published in Scrip
Executive Summary
Researchers at the National Institutes of Health (NIH) had reason to cheer on 7 May after reaching the 1,500 study participant enrollment goal for the Phase II portion of the agency’s Liberian PREVAIL trial testing two experimental Ebola vaccines.